PharmaCyte director granted 119,170 stock options

PharmaCyte Biotech, Inc. director Wayne Remell Walker received a grant of stock options covering 119,170 shares of common stock.

Rhea-AI Filing Summary

PharmaCyte Biotech, Inc. director Wayne Remell Walker received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036, with 119,170 derivative securities held after this grant.

According to the filing, the options will vest in full on the date of the company’s next annual meeting of stockholders, subject to Mr. Walker’s continued service. This award is characterized as a grant or other acquisition of derivative securities rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 119,170 shares

Grant/Award 1 txn

Insider WALKER WAYNE REMELL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	119,170	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 119,170 contracts (Direct)

Footnotes (1)

1. F1. The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker.

Key Figures

Options granted: 119,170 options Exercise price: $0.67 per share Underlying shares: 119,170 shares +2 more

5 metrics

Options granted 119,170 options Stock Option (Right to Buy) grant to director

Exercise price $0.67 per share Conversion or exercise price of stock options

Underlying shares 119,170 shares Common stock underlying the options

Post-grant derivative holdings 119,170 derivative securities Total derivative securities following transaction

Option expiration date March 30, 2036 Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, derivative securities, vest in full

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

derivative securities financial

"derivativeTransactionCount: 1 derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vest in full financial

"The options shall vest in full on the date of the Issuer's next annual meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PharmaCyte Biotech (PMCB) director Wayne Remell Walker receive in this Form 4 filing?

Wayne Remell Walker received a grant of stock options covering 119,170 shares of PharmaCyte Biotech common stock. These options are a compensation-related award, not an open-market purchase, and are classified as a grant, award, or other acquisition of derivative securities.

What is the exercise price and expiration date of Wayne Walker’s PharmaCyte (PMCB) stock options?

The granted stock options have an exercise price of $0.67 per share and expire on March 30, 2036. This means Walker can buy PharmaCyte common stock at $0.67 per share any time before the March 30, 2036 expiration, once the options are vested.

When do Wayne Walker’s new PharmaCyte (PMCB) stock options vest?

The options will vest in full on the date of PharmaCyte Biotech’s next annual meeting of stockholders, subject to Wayne Walker’s continued service. Vesting in full means all 119,170 optioned shares become exercisable at that meeting date if he remains in his role.

How many PharmaCyte (PMCB) derivative securities does Wayne Walker hold after this grant?

After this grant, Wayne Walker holds 119,170 derivative securities related to PharmaCyte Biotech. These represent stock options giving him the right to acquire 119,170 shares of common stock at an exercise price of $0.67 per share, subject to vesting and expiration terms.

Was Wayne Walker’s PharmaCyte (PMCB) Form 4 transaction a market buy or sell of shares?

The Form 4 shows a grant, award, or other acquisition of stock options, not a market buy or sell of common shares. The transaction code “A” and description indicate a compensation-related award of derivative securities rather than an open-market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 06:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WALKER WAYNE REMELL

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NEVADA 89169

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.67	03/31/2026		A		119,170		(1)	03/30/2036	Common Stock	119,170	$0	119,170	D

Explanation of Responses:

1. The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Walker.

	/s/ Wayne R. Walker	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)